JP2021536237A5 - - Google Patents
Info
- Publication number
- JP2021536237A5 JP2021536237A5 JP2021510710A JP2021510710A JP2021536237A5 JP 2021536237 A5 JP2021536237 A5 JP 2021536237A5 JP 2021510710 A JP2021510710 A JP 2021510710A JP 2021510710 A JP2021510710 A JP 2021510710A JP 2021536237 A5 JP2021536237 A5 JP 2021536237A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- motif
- treg
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024111754A JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1814203.4 | 2018-08-31 | ||
| GBGB1814203.4A GB201814203D0 (en) | 2018-08-31 | 2018-08-31 | Engineered regulatory t cell |
| PCT/GB2019/052422 WO2020044055A1 (en) | 2018-08-31 | 2019-08-30 | Engineered regulatory t cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111754A Division JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021536237A JP2021536237A (ja) | 2021-12-27 |
| JP2021536237A5 true JP2021536237A5 (https=) | 2022-09-05 |
Family
ID=63920789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510710A Pending JP2021536237A (ja) | 2018-08-31 | 2019-08-30 | 改変された制御性ｔ細胞 |
| JP2024111754A Pending JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111754A Pending JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210338726A1 (https=) |
| EP (1) | EP3844264A1 (https=) |
| JP (2) | JP2021536237A (https=) |
| KR (1) | KR20210054543A (https=) |
| CN (1) | CN112969784A (https=) |
| AU (1) | AU2019333012A1 (https=) |
| CA (1) | CA3110012A1 (https=) |
| GB (2) | GB201814203D0 (https=) |
| IL (1) | IL280942A (https=) |
| SG (1) | SG11202101668TA (https=) |
| WO (1) | WO2020044055A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3714944A1 (en) * | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| CN111819192A (zh) | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| JP7436383B2 (ja) | 2018-04-18 | 2024-02-21 | ユーシーエル ビジネス リミテッド | 操作された調節性ｔ細胞 |
| AU2020232216B2 (en) | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| PE20211902A1 (es) | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
| US12528856B2 (en) | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| MX2022010340A (es) | 2020-02-24 | 2022-09-19 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas. |
| CN115427440A (zh) * | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| WO2021207150A1 (en) * | 2020-04-06 | 2021-10-14 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| CN111393533B (zh) * | 2020-04-16 | 2021-05-11 | 成都仕康美生物科技有限公司 | 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途 |
| GB202007842D0 (en) | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| KR20230019157A (ko) * | 2020-06-01 | 2023-02-07 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유도 조절 t 세포, 이의 제조 방법, 및 용도 |
| CA3178900A1 (en) | 2020-06-11 | 2021-12-16 | Marc MARTINEZ-LLORDELLA | Trem2 chimeric receptor |
| CN111849916B (zh) * | 2020-07-21 | 2021-08-27 | 广东先康达生物科技有限公司 | 一种免疫细胞及其制剂与应用 |
| GB202013477D0 (en) | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| AU2021373326A1 (en) | 2020-11-09 | 2023-06-22 | Quell Therapeutics Ltd | Method for cryopreserving engineered tregs |
| GB202017678D0 (en) | 2020-11-09 | 2020-12-23 | Quell Therapeutics Ltd | Method for cryopreserving engineered tregs |
| EP4267601A1 (en) | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Inducible signalling protein |
| CA3221900A1 (en) * | 2021-06-08 | 2022-12-15 | Stanley Hersh Appel | Methods for producing regulatory t cell (treg) populations, treg compositions and methods for treatment |
| GB202108366D0 (en) | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Multichain chimeric antigen receptor |
| GB202108364D0 (en) | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Chimeric receptor |
| TW202321286A (zh) | 2021-09-21 | 2023-06-01 | 英商圭爾醫療有限公司 | 抗p75ntr嵌合抗原受體 |
| EP4405385A1 (en) | 2021-09-21 | 2024-07-31 | Quell Therapeutics Limited | Anti-trem2 chimeric antigen receptor |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| WO2023102712A1 (zh) * | 2021-12-07 | 2023-06-15 | 深圳市先康达生命科学有限公司 | 一种基因生物制剂及其制备方法和应用 |
| US20250017967A1 (en) | 2021-12-17 | 2025-01-16 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| EP4453022A1 (en) | 2021-12-22 | 2024-10-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4479143A1 (en) * | 2022-02-18 | 2024-12-25 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance |
| EP4496883A1 (en) | 2022-03-22 | 2025-01-29 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| IL318954A (en) * | 2022-08-26 | 2025-04-01 | Sonoma Biotherapeutics Inc | Recombinant interleukin-2-related receptors and methods of use |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| CN120981484A (zh) | 2023-01-23 | 2025-11-18 | 汉诺威医学院 | 抗entpd3嵌合抗原受体 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| AU2024219048A1 (en) | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194642A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t regulatory cell |
| WO2024254450A1 (en) * | 2023-06-07 | 2024-12-12 | Cellmidi Company Limited | Improved endodomains and immune cells comprising the same |
| CN121586727A (zh) | 2023-06-21 | 2026-02-27 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| EP2970985A1 (en) * | 2013-03-14 | 2016-01-20 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| WO2016127257A1 (en) * | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| CA3004299A1 (en) * | 2015-11-05 | 2017-05-11 | City Of Hope | Methods for preparing cells for adoptive t cell therapy |
| JP7123794B2 (ja) * | 2015-12-09 | 2022-08-23 | メモリアル スローン ケタリング キャンサー センター | 免疫細胞組成物及びそれを使用する方法 |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| JP2019518460A (ja) | 2016-06-16 | 2019-07-04 | メモリアル スローン ケタリング キャンサー センター | 操作されたＴｒｅｇ細胞 |
| CN109863242A (zh) * | 2016-08-30 | 2019-06-07 | 纪念斯隆-凯特林癌症中心 | 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法 |
| JP7227912B2 (ja) * | 2017-02-08 | 2023-02-24 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キメラ抗原受容体の調節 |
| US11827705B2 (en) * | 2017-03-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Methods to protect transplanted tissue from rejection |
-
2018
- 2018-08-31 GB GBGB1814203.4A patent/GB201814203D0/en not_active Ceased
-
2019
- 2019-08-30 US US17/272,126 patent/US20210338726A1/en active Pending
- 2019-08-30 EP EP19763058.5A patent/EP3844264A1/en active Pending
- 2019-08-30 KR KR1020217009384A patent/KR20210054543A/ko active Pending
- 2019-08-30 CN CN201980067986.5A patent/CN112969784A/zh active Pending
- 2019-08-30 AU AU2019333012A patent/AU2019333012A1/en not_active Abandoned
- 2019-08-30 SG SG11202101668TA patent/SG11202101668TA/en unknown
- 2019-08-30 GB GB2104653.7A patent/GB2591929B/en active Active
- 2019-08-30 WO PCT/GB2019/052422 patent/WO2020044055A1/en not_active Ceased
- 2019-08-30 JP JP2021510710A patent/JP2021536237A/ja active Pending
- 2019-08-30 CA CA3110012A patent/CA3110012A1/en active Pending
-
2021
- 2021-02-17 IL IL280942A patent/IL280942A/en unknown
-
2024
- 2024-07-11 JP JP2024111754A patent/JP2024138456A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021536237A5 (https=) | ||
| GB2591929A (en) | Engineered regulatory T Cell | |
| Leung | Use of NK cell activity in cure by transplant | |
| Fierabracci et al. | Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles | |
| US20250283040A1 (en) | Methods to Expand a T Regulatory Cell Master Cell Bank | |
| GB2609103A (en) | Chimeric receptors for use in engineered cells | |
| EP4545639A2 (en) | Engineered gamma delta t-cells | |
| JP2008508885A5 (https=) | ||
| JP2019536461A5 (https=) | ||
| JP2019050826A (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| JP2020513844A5 (https=) | ||
| EP3324984A1 (en) | T cells for expression of chimeric antigen receptors and other receptors | |
| EP3882337A1 (en) | Compositions and methods for diminishing an immune response | |
| CN102876630A (zh) | 一种高效分离和扩增人脐带血间充质干细胞的方法 | |
| ZA200601074B (en) | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations | |
| US10758573B2 (en) | Compositions and methods for enrichment of cells | |
| JP2012527237A (ja) | 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法 | |
| JP2016539635A (ja) | 抗原特異的調節性ｔ細胞の誘導方法 | |
| GB2614158A (en) | Nucleic acid constructs for expressing polypeptides in cells | |
| Ulusoy et al. | Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice | |
| Moirangthem et al. | A DL-4-and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors | |
| US20170106021A1 (en) | Compositions enriched for hox11+ stem cells and methods of preparing the same | |
| EP4289859A1 (en) | Fusion protein for maintenance of regulatory t-cells | |
| JP2007521803A (ja) | レギュレーター／サプレッサーｔリンパ球の同定および調製のための方法、その組成物、並びにその使用 | |
| JP2020517289A5 (https=) |